BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.82%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.17B
AUM Growth
+$6.17B
(+0.29%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
39.22%
Holding
177
New
11
Increased
57
Reduced
71
Closed
15
Top Buys
| 1 |
Evolent Health
EVH
|
$28.3M |
| 2 |
Exact Sciences
EXAS
|
$19.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
Abbott
ABT
|
$15.7M |
| 5 |
Inspire Medical Systems
INSP
|
$14.8M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$36.5M |
| 2 |
Insmed
INSM
|
$36.2M |
| 3 |
argenx
ARGX
|
$32M |
| 4 |
Charles River Laboratories
CRL
|
$31.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$30.5M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Industrials | 0.04% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Gilead Sciences
GILD
$140B
| $3.86M | 0.06% |
46,027
+7,093
| +18% | +$595K |
|
102
Cardinal Health
CAH
$36B
| $3.34M | 0.05% |
30,224
-2,358
| -7% | -$261K |
|
103
AstraZeneca
AZN
$255B
| $2.61M | 0.04% |
33,500
-8,700
| -21% | -$678K |
|
104
Recursion Pharmaceuticals
RXRX
$2.02B
| $2.59M | 0.04% |
392,881
-32,929
| -8% | -$217K |
|
|
ACCD
105
DELISTED
Accolade, Inc. Common Stock
ACCD
| $2.47M | 0.04% |
640,865
-201,712
| -24% | -$777K |
|
106
Bristol-Myers Squibb
BMY
$96.7B
| $1.91M | 0.03% |
+36,825
| New | +$1.91M |
|
107
Encompass Health
EHC
$12.5B
| $1.86M | 0.03% |
19,233
+5,365
| +39% | +$518K |
|
|
MTEM
108
DELISTED
Molecular Templates, Inc.
MTEM
| $1.8M | 0.03% |
1,279,820
| – | – |
|
109
Dr. Reddy's Laboratories
RDY
$11.8B
| $1.64M | 0.03% |
20,595
-2,733
| -12% | -$217K |
|
110
Summit Therapeutics
SMMT
$17.5B
| $1.4M | 0.02% |
+64,094
| New | +$1.4M |
|
111
CVS Health
CVS
$93B
| $1.39M | 0.02% |
22,066
| – | – |
|
112
Vaxcyte
PCVX
$4.17B
| $1.37M | 0.02% |
11,981
-2,229
| -16% | -$255K |
|
113
Teva Pharmaceuticals
TEVA
$21.5B
| $1.28M | 0.02% |
70,821
-83,949
| -54% | -$1.51M |
|
114
Doximity
DOCS
$12.6B
| $1.27M | 0.02% |
29,060
-43,095
| -60% | -$1.88M |
|
115
Certara
CERT
$1.69B
| $1.12M | 0.02% |
95,924
| – | – |
|
116
BioNTech
BNTX
$24.1B
| $1.04M | 0.02% |
+8,721
| New | +$1.04M |
|
117
Zoetis
ZTS
$67.6B
| $1.03M | 0.02% |
5,284
+2,343
| +80% | +$458K |
|
118
Viking Therapeutics
VKTX
$3.02B
| $1.02M | 0.02% |
16,179
+11,779
| +268% | +$746K |
|
119
Alphabet (Google) Class C
GOOG
$2.79T
| $1M | 0.02% |
6,000
| – | – |
|
120
Tenet Healthcare
THC
$16.5B
| $935K | 0.02% |
5,625
+211
| +4% | +$35.1K |
|
121
Sanofi
SNY
$122B
| $871K | 0.01% |
+15,109
| New | +$871K |
|
122
Krystal Biotech
KRYS
$4.35B
| $870K | 0.01% |
4,779
+581
| +14% | +$106K |
|
123
Rhythm Pharmaceuticals
RYTM
$6.75B
| $823K | 0.01% |
15,700
+2,700
| +21% | +$141K |
|
124
Amneal Pharmaceuticals
AMRX
$3B
| $636K | 0.01% |
76,414
+13,654
| +22% | +$114K |
|
125
Cytokinetics
CYTK
$5.98B
| $578K | 0.01% |
10,941
-5,718
| -34% | -$302K |
|